Resultado de búsqueda
29 de abr. de 2021 · The use of DTG-containing two-drug regimens (2DR), and, in particular, of DTG plus lamivudine (3TC), is one of the most promising solutions to the need to ease the management of HIV treatment without harming its efficacy and safety.
Dolutegravir/lamivudine/tenofovir (DTG/3TC/TDF) is a fixed-dose combination antiretroviral medication used to treat HIV/AIDS. [1] It is a combination of dolutegravir, lamivudine, and tenofovir disoproxil. [1]
El ensayo clínico aleatorizado y doble ciego SINGLE 16 demostró la superioridad de DTG/3TC/ABC frente a EFV/FTC/TDF a las 48 semanas, que se mantuvo en la semana 144.
22 de may. de 2015 · Además, DTG ha demostrado ser superior a la combinación de darunavir y ritonavir tanto en combinación con ABC/3TC como con TDF/FTC en pacientes naïve, según el ensayo Flamingo. Asimismo, en el Spring-2, esta pastilla ha mostrado su no inferioridad frente a raltegravir (RAL) administrado dos veces al día.
1 de oct. de 2021 · Objectives: Dolutegravir/lamivudine (DTG/3TC) is indicated for treatment-naive and experienced people with HIV; however, questions remain about its utility in a test-and-treat setting because of potential transmitted resistance and baseline hepatitis B virus (HBV) co-infection.
23 de oct. de 2019 · The first-ever 2-drug regimen approved for the treatment of HIV-1 infection for treatment-naive people living with HIV (PLWH), consisting of the integrase inhibitor dolutegravir (DTG) and the nucleoside reverse transcriptase inhibitor (NRTI) lamivudine (3TC), is reviewed in this paper.
22 de jul. de 2024 · DTG + 3TC dual therapy demonstrates effectiveness in treatment naïve PLWH with high baseline HIV RNA VL, suggesting its potential as a first line regimen for all treatment naïve PLWH. Antiretroviral therapy (ART) has transformed HIV management, with various regimens available.
